These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9563925)

  • 1. Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid: a randomized prospective trial.
    Abdelmalek MF; Harrison ME; Gross JB; Poterucha JJ; Gossard AA; Spivey JR; Rakela J; Lindor KD
    J Clin Gastroenterol; 1998 Mar; 26(2):130-4. PubMed ID: 9563925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis: controlled randomized trial in 203 patients.
    Boucher E; Guyader D; Jacquelinet S; Andre P; Mendler MH; Turlin B; Canva V; Nousbaum JB; Bernard PH; Nouel O; Raabe JJ; Dao T; Gasser P; Verger P; Boutin J; Bergerault P; Joram F; Colmar P; Messner M; Brissot P; Deugnier Y
    Dig Liver Dis; 2000; 32(1):29-33. PubMed ID: 10975752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C.
    Younossi ZM; Perrillo RP
    Semin Liver Dis; 1999; 19 Suppl 1():95-102. PubMed ID: 10349697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up.
    Angelico M; Gandin C; Pescarmona E; Rapicetta M; Del Vecchio C; Bini A; Spada E; Baroni CD; Capocaccia L
    Am J Gastroenterol; 1995 Feb; 90(2):263-9. PubMed ID: 7847298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy of interferon-alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis.
    Senturk H; Uzunalimoglu O; Batur Y; Simsek I; Mert A; Ozbay G; Cetinkaya H; Ersoz G; Tabak F; Akbaylar H; Akdogan M; Dokmeci A; Sonsuz A; Ozenirler S; Erden E; Tozum N
    Dig Dis Sci; 1997 Jul; 42(7):1438-44. PubMed ID: 9246043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.
    Reichard O; Norkrans G; Frydén A; Braconier JH; Sönnerborg A; Weiland O
    Lancet; 1998 Jan; 351(9096):83-7. PubMed ID: 9439491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon plus ursodeoxycholic acid versus interferon in the treatment of chronic C viral hepatitis.
    Clerici C; Distrutti E; Gentili G; Solinas A; Miglietti M; Balò S; Giansanti M; Rusticali AG; Morselli-Labate AM; Morelli A
    Minerva Med; 1997 May; 88(5):219-25. PubMed ID: 9250283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of ursodeoxycholic acid in association with alpha-interferon for chronic hepatitis C in alpha-interferon non-responder patients.
    Fabbri C; Marchetto S; Pezzoli A; Accogli E; Fusaroli P; Azzaroli F; Jaboli MF; Mazzeo C; Montagnani M; Festi D; Roda E; Mazzella G
    Eur J Gastroenterol Hepatol; 2000 May; 12(5):511-5. PubMed ID: 10833093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease.
    Lirussi F; Beccarello A; Bortolato L; Morselli-Labate AM; Crovatto M; Ceselli S; Santini G; Crepaldi G
    Liver; 1999 Oct; 19(5):381-8. PubMed ID: 10533795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon alpha-2b in combination with ribavirin for the treatment of chronic hepatitis C: assessment of virological, biochemical and histological treatment response.
    Petrenkiene V; Gudinaviciene I; Jonaitis L; Kupcinskas L
    Medicina (Kaunas); 2004; 40(6):538-46. PubMed ID: 15208476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of interferon-alpha plus ursodeoxycholic acid versus interferon plus placebo in patients with chronic hepatitis C resistant to interferon.
    Poupon RE; Bonnand AM; Queneau PE; Trépo C; Zarski JPí ; Vetter D; Raabe JJ; Thieffin G; Larrey D; Grangé JD; Capron JP; Serfaty L; Chrétien Y; St Marc Girardin MF; Mathiex-Fortunet H; Zafrani ES; Guéchot J; Beuers U; Paumgartner G; Poupon R
    Scand J Gastroenterol; 2000 Jun; 35(6):642-9. PubMed ID: 10912666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
    Scott LJ; Perry CM
    Drugs; 2002; 62(3):507-56. PubMed ID: 11827565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
    Marcellin P; Boyer N; Gervais A; Martinot M; Pouteau M; Castelnau C; Kilani A; Areias J; Auperin A; Benhamou JP; Degott C; Erlinger S
    Ann Intern Med; 1997 Nov; 127(10):875-81. PubMed ID: 9382365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
    de Lédinghen V; Trimoulet P; Winnock M; Foucher J; Bourlière M; Desmorat H; Canva V; Capron D; Lévy S; Mion F; Mannant PR; Chêne G; Fleury H; Couzigou P; Bernard PH;
    J Hepatol; 2002 May; 36(5):672-80. PubMed ID: 11983451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.
    Maddrey WC
    Semin Liver Dis; 1999; 19 Suppl 1():67-75. PubMed ID: 10349694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients.
    el-Zayadi A; Selim O; Haddad S; Simmonds P; Hamdy H; Badran HM; Shawky S
    Ital J Gastroenterol Hepatol; 1999; 31(6):472-5. PubMed ID: 10575565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C.
    McHutchison JG; Poynard T
    Semin Liver Dis; 1999; 19 Suppl 1():57-65. PubMed ID: 10349693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France.
    Pol S; Couzigou P; Bourlière M; Abergel A; Combis JM; Larrey D; Tran A; Moussalli J; Poupon R; Berthelot P; Bréchot C
    J Hepatol; 1999 Jul; 31(1):1-7. PubMed ID: 10424277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple combination of interferon alpha-2b, ribavirin, and amantadine for treatment of chronic hepatitis C.
    Younossi ZM; Mullen KD; Hodnick S; Barnes DS; Carey WD; McCullough AC; Easley K; Gramlich T; Liebermann BY
    J Clin Gastroenterol; 2003; 36(5):427-30. PubMed ID: 12702987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.